Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis–related pulmonary artery hypertension and cutaneous vascular complications
暂无分享,去创建一个
S. Kaur | D. Misra | V. Sreenivas | U. Kumar | Sankalp S. Gokhle | Sankalp S. Gokhle | Sankalp S. Gokhle
[1] Z. Jing,et al. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension , 2009, Hypertension Research.
[2] V. Vidjak,et al. One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension. , 2009, Collegium Antropologicum.
[3] F. Walz,et al. Rasche Abheilung von akralen Ulzera bei systemischer Sklerodermie unter Sildenafil , 2008, Der Hautarzt.
[4] R. Barst,et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.
[5] R. Gerszten,et al. Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .
[6] N. Sinha,et al. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. , 2007, International journal of cardiology.
[7] Chen Wang,et al. [Efficacy and safety of sildenafil therapy in pulmonary artery hypertension: a meta-analysis]. , 2007, Zhonghua yi xue za zhi.
[8] T. Levien. Phosphodiesterase Inhibitors in Raynaud's Phenomenon , 2006, The Annals of pharmacotherapy.
[9] S. Malhotra,et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. , 2006, American heart journal.
[10] M. Peberdy,et al. Prognostic value of heart rate recovery in patients with heart failure. , 2006, American heart journal.
[11] D. Abraham,et al. Mechanisms and consequences of fibrosis in systemic sclerosis , 2006, Nature Clinical Practice Rheumatology.
[12] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[13] M. Böhm,et al. Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.
[14] D. Pennell,et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. , 2005, American journal of respiratory and critical care medicine.
[15] S. Rosenkranz,et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. , 2003, Annals of internal medicine.
[16] S. Kimmel,et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.
[17] D. Isenberg,et al. Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? , 2002, Arthritis and rheumatism.
[18] C. Narasimhan,et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. , 2002, Indian heart journal.
[19] Hiroshi Watanabe,et al. Sildenafil for primary and secondary pulmonary hypertension , 2002, Clinical pharmacology and therapeutics.
[20] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.
[21] G. Jackson,et al. Effects of sildenafil citrate on human hemodynamics. , 1999, The American journal of cardiology.
[22] G. Gemne,et al. Diagnostics of hand-arm system disorders in workers who use vibrating tools. , 1997, Occupational and environmental medicine.
[23] M. Meurer,et al. [Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil]. , 2008, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[24] P. Grenier,et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. , 2006, Arthritis and rheumatism.